Online inquiry

IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2228MR)

This product GTTS-WQ2228MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VWF gene. The antibody can be applied in Acute coronary syndrome (ACS), Thrombotic thrombocytopenia purpura (TTP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000552.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7450
UniProt ID P04275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2228MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13868MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ11348MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ1983MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ10333MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ118MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ10573MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ6663MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ15277MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW